Balyasny Asset Management LLC Cytom X Therapeutics, Inc. Transaction History

Balyasny Asset Management LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$1.41 - $2.74 $45,008 - $87,463	31,921 New	31,921 $69,000
Q4 2022 Feb 14, 2023	BUY	$1.19 - $1.91 $23,807 - $38,211	20,006 Added 135.23%	34,800 $55,000
Q3 2022 Nov 14, 2022	SELL	$1.23 - $1.97 $2,162 - $3,463	-1,758 Reduced 10.62%	14,794 $21,000
Q2 2022 Aug 15, 2022	BUY	$1.53 - $2.89 $25,324 - $47,835	16,552 New	16,552 $30,000
Q3 2021 Nov 15, 2021	SELL	$4.32 - $6.43 $43,454 - $64,679	-10,059 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$6.33 - $9.91 $63,673 - $99,684	10,059 New	10,059 $64,000
Q3 2018 Nov 14, 2018	SELL	$18.04 - $26.41 $300,041 - $439,251	-16,632 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$21.38 - $29.68 $24,736 - $34,339	1,157 Added 7.48%	16,632 $380,000
Q1 2018 May 15, 2018	BUY	$21.76 - $34.22 $336,736 - $529,554	15,475 New	15,475 $440,000

50.4M

112K

8.3K

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $66M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.